Strategic Advocates’s Organon & Co OGN Stock Holding History

Strategic Advocates’s Portfolio OGN Stock Details OGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$8	–	497
2025 Q4	$8	Hold	1	–	–	﹤0.01%	633
2025 Q3	$13	Buy	+1	New	+$10	﹤0.01%	609

Other funds holding OGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KBG

Kahn Brothers Group New York $564M AUM 25.3% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PMG

Private Management Group Irvine, California $3.47B AUM 13.39% 1-Year Est. Return

Strategic Advocates's OGN Position: Q1 2026 in Review

Strategic Advocates sold out of Organon & Co (OGN) in Q1 2026, closing a stake of 1 share — an estimated $8 sold.

Strategic Advocates first reported a position in OGN in Q3 2025 and held it in 2 quarters. The position peaked at $13 in Q3 2025. 603 funds tracked by Wall St. Rank hold OGN as of Q1 2026.

Strategic Advocates reported no remaining Organon & Co position as of Q1 2026 after selling out during the quarter.
Strategic Advocates sold 1 Organon & Co share in Q1 2026, an estimated $8.
Strategic Advocates first reported a position in Organon & Co in Q3 2025 and held it in 2 quarters.
Strategic Advocates's Organon & Co position peaked at $13 in Q3 2025.
603 funds tracked by Wall St. Rank held Organon & Co as of Q1 2026.

Based on Strategic Advocates's 13F filing for Q1 2026, filed 15 May 2026.